Check out our COVID-19 dedicated page for tenders related to medical equipment needs.

The Conference on the Future of Europe is your chance to share your ideas and shape the future of Europe. Make your voice heard!

Services - 624705-2021

Submission deadline has been amended by:  24896-2022
07/12/2021    S237

Belgium-Brussels: Research and experimental development services

2021/S 237-624705

Contract notice

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: Sciensano
National registration number: 0693.876.830_118
Postal address: Rue Juliette Wytsman 14
Town: Bruxelles
NUTS code: BE Belgique / België
Postal code: 1050
Country: Belgium
Contact person: Service Achat
E-mail: purchasing@sciensano.be
Telephone: +32 26425371
Internet address(es):
Main address: www.sciensano.be
Address of the buyer profile: https://enot.publicprocurement.be/enot-war/preViewNotice.do?noticeId=430790
I.1)Name and addresses
Official name: ALLEANZA CONTRO IL CANCRO (ACC)
Postal address: VIA GIORGIO RIBOTTA 5
Town: Roma
NUTS code: IT Italia
Postal code: 00144
Country: Italy
E-mail: roberta.carbone@ieo.it
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.alleanzacontroilcancro.it
I.1)Name and addresses
Official name: INSTITUT CURIE (IC)
Postal address: Rue d'Ulm 26
Town: Paris
NUTS code: FR France
Postal code: 75231
Country: France
E-mail: maud.kamal@curie.fr
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://institut-curie.org/
I.1)Name and addresses
Official name: INSTITUT CATALA D'ONCOLOGIA (ICO)
Postal address: AV GRAN VIA DE L'HOSPITALET 199-203
Town: L'HOSPITALET DEL LLOBREGAT
NUTS code: ES España
Postal code: 08908
Country: Spain
E-mail: jmborras@iconcologia.net
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://ico.gencat.cat/en/inici/
I.1)Name and addresses
Official name: INSTITUT JULES BORDET (IJB)
Postal address: RUE HEGER BORDET 1
Town: Brussels
NUTS code: BE100 Arr. de Bruxelles-Capitale / Arr. Brussel-Hoofdstad
Postal code: 1000
Country: Belgium
E-mail: philippe.aftimos@bordet.be
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.bordet.be
I.1)Name and addresses
Official name: LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (LMU MUENCHEN)
Postal address: GESCHWISTER SCHOLL PLATZ 1
Town: Muenchen
NUTS code: DE Deutschland
Postal code: 80539
Country: Germany
E-mail: martin.dreyling@med.uni-muenchen.de
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.klinikum.uni-muenchen.de
I.1)Name and addresses
Official name: CHARITE - UNIVERSITAETSMEDIZIN BERLIN (HC)
Postal address: Chariteplatz 1
Town: Berlin
NUTS code: DE Deutschland
Postal code: 10117
Country: Germany
E-mail: lars.bullinger@charite.de
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.charite.de/en/
I.1)Name and addresses
Official name: HOSPICES CIVILS DE LYON (HCL)
Postal address: QUAI DES CELESTINS 3
Town: Lyon
NUTS code: FR France
Postal code: 69002
Country: France
E-mail: pierre.sujobert@chu-lyon.fr
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.chu-lyon.fr/fr
I.2)Information about joint procurement
The contract involves joint procurement
In the case of joint procurement involving different countries, state applicable national procurement law:

Ce marché précommercial (PCP) est réalisé par SCIENSANO, qui a été nommé acheteur principal. Le droit national applicable aux marchés publics est le droit belge.

I.3)Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at: https://enot.publicprocurement.be/enot-war/preViewNotice.do?noticeId=430790
Additional information can be obtained from the abovementioned address
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Achat précommercial pour l’achat de services de R&D pour le développement d’une solution d’analyse dans des biopsies liquides de tumeurs solides fondées sur la technologie NGS

Reference number: Sciensano-000-ONCNGS (1)-F02_0
II.1.2)Main CPV code
73100000 Research and experimental development services
II.1.3)Type of contract
Services
II.1.4)Short description:

The mutational profiling of tumours requires complex, invasive and expensive procedures but is rapidly becoming essential for an efficient and adequate provision of care for cancer patients, especially when the disease has already advanced to metastatic conditions, in which the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access to tumour tissue remains a limiting factor for the assessment of biomarkers, and mounting evidence suggests that may even be inadequate to capture the clonal heterogeneity that often drives resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative that offers the additional possibility of serially monitoring disease evolution and the potential to obtain a more comprehensive picture of the tumour genetic heterogeneity. However, the current development trajectory for large cfDNA tests is heavily reliant on costly, high throughput centralized sequencing and appears ill-suited for European common practice.

The oncNGS PCP aims at developing an integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours (including appropriate haematological indications) based on NGS technology.

This PCP tackles the common global unmet need in oncology to profile multiple tumours at the molecular level in the broadest possible way, promoting an economically sustainable and de-centralised model that allows a secure and transparent access to sensitive data. All partners in this consortium do agree that they face a common challenge in providing ‘the best NGS tests, for all solid and lymphoid tumours, forever’. They agree that a commonly identified procurement meets a need that is shared by all procurers in the Buyers Group of the project that forms the object of the here proposed PCP procurement ‘oncNGS’.

More information regarding the goal of the oncNGS PCP and the PCP Challenge can be found in Annex 2 – Challenge Brief, as well as the technical and functional specifications.

II.1.5)Estimated total value
Value excluding VAT: 7 073 554.00 EUR
II.1.6)Information about lots
This contract is divided into lots: no
II.2)Description
II.2.2)Additional CPV code(s)
33000000 Medical equipments, pharmaceuticals and personal care products
38000000 Laboratory, optical and precision equipments (excl. glasses)
48180000 Medical software package
73100000 Research and experimental development services
73300000 Design and execution of research and development
73000000 Research and development services and related consultancy services
72212460 Analytical, scientific, mathematical or forecasting software development services
72212461 Analytical or scientific software development services
72000000 IT services: consulting, software development, Internet and support
71900000 Laboratory services
II.2.3)Place of performance
NUTS code: BE Belgique / België
Main site or place of performance:

La R&D sera principalement réalisée en Europe.

Les tests devraient avoir lieu à Bruxelles (Belgique), Paris, Lyon (France), Berlin, Munich (Allemagne), Barcelone (Espagne), Milan, Rome (Italie)

II.2.4)Description of the procurement:

The mutational profiling of tumours requires complex, invasive and expensive procedures but is rapidly becoming essential for an efficient and adequate provision of care for cancer patients, especially when the disease has already advanced to metastatic conditions, in which the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access to tumour tissue remains a limiting factor for the assessment of biomarkers, and mounting evidence suggests that may even be inadequate to capture the clonal heterogeneity that often drives resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative that offers the additional possibility of serially monitoring disease evolution and the potential to obtain a more comprehensive picture of the tumour genetic heterogeneity. However, the current development trajectory for large cfDNA tests is heavily reliant on costly, high throughput centralized sequencing and appears ill-suited for European common practice.

The oncNGS PCP aims at developing an integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours (including appropriate haematological indications) based on NGS technology.

This PCP tackles the common global unmet need in oncology to profile multiple tumours at the molecular level in the broadest possible way, promoting an economically sustainable and de-centralised model that allows a secure and transparent access to sensitive data. All partners in this consortium do agree that they face a common challenge in providing ‘the best NGS tests, for all solid and lymphoid tumours, forever’. They agree that a commonly identified procurement meets a need that is shared by all procurers in the Buyers Group of the project that forms the object of the here proposed PCP procurement ‘oncNGS’.

More information regarding the goal of the oncNGS PCP and the PCP Challenge can be found in Annex 2 – Challenge Brief, as well as the technical and functional specifications.

II.2.5)Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 38
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 874467

II.2.14)Additional information

Voir le document PCP et autres documents du marché joints

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.3)Technical and professional ability
Minimum level(s) of standards possibly required:

Classe: N/A, Catégorie: N/A

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: no
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
Notice number in the OJ S: 2021/S 076-194474
IV.2.2)Time limit for receipt of tenders or requests to participate
Date: 02/02/2022
Local time: 14:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates
IV.2.4)Languages in which tenders or requests to participate may be submitted:
English, French, Dutch
IV.2.7)Conditions for opening of tenders
Date: 02/02/2022
Local time: 14:00

Section VI: Complementary information

VI.1)Information about recurrence
This is a recurrent procurement: no
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: Conseil d'Etat
Town: Bruxelles
Postal code: 1040
Country: Belgium
VI.5)Date of dispatch of this notice:
02/12/2021